Metastatic Castration Sensitive Prostate Cancer (mCSPC) research hub
3 indexed studies · 2 currently recruiting
- recruitingPHASE3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study looks at a new drug, mevrometostat, combined with enzalutamide for men with prostate cancer that has spread. It compares this combination to enzalutamide alone, to see if it works better for those not yet treated with specific hormone therapies.
United States · Argentina · Australia - recruitingNA
A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers
This study looks at TEMPO, an online program for men with prostate cancer and their family caregivers. It aims to help them manage cancer challenges and anxiety. We want to find the best way to offer TEMPO to improve their health and well-being.
Canada - active not recruitingPHASE3
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
This study looks at a new combination of medicines, enzalutamide and leuprolide, for men with prostate cancer that hasn't spread but is considered high-risk. The goal is to see how safe and effective this combination is in slowing down the cancer.
United States · Australia · Austria